Cited 0 times in Scipus Cited Count

Topical epidermal growth factor spray for the treatment of chronic diabetic foot ulcers: A phase III multicenter, double-blind, randomized, placebo-controlled trial

Park, KH | Han, SH | Hong, JP | Han, SK | Lee, DH  | Kim, BS | Ahn, JH | Lee, JW
Diabetes research and clinical practice, 142. : 335-344, 2018
Journal Title
Diabetes research and clinical practice
AIMS: This study was conducted to evaluate the efficacy and safety of a novel spray-applied growth factor therapy containing recombinant human epidermal growth factor (rhEGF) for the treatment of chronic diabetic foot ulcers (DFU).
METHODS: This study was a phase III double-blind, randomized, placebo-controlled trial. 167 adult patients at six medical centers were randomized to receive routine wound care plus either topical spray treatment with 0.005% rhEGF (n=82) or an equivalent volume of saline spray (n=85) twice a day until ulcer healing or for up to 12 weeks.
RESULTS: Demographics, medical status, and wound characteristics were comparable between rhEGF and placebo groups. More patients in the rhEGF group significantly had complete wound healing compared to placebo (73.2% versus 50.6%, respectively: P=.001). Wound healing velocity was faster in the rhEGF group (P=.029) regardless of HbA1c levels. The rhEGF group had a shorter median time to 50% ulcer size reduction (21 versus 35 days: hazard ratio=3.13, P<.001) and shorter time to complete ulcer healing (56 versus 84 days: hazard ratio=2.13, P<.001).
CONCLUSIONS: This study confirms that application of spray-applied rhEGF in DFU patients results in faster healing velocity and higher complete healing rate regardless of HbA1c levels.


Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Orthopedic Surgery
Ajou Authors
이, 두형
Files in This Item:
There are no files associated with this item.


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.